Skip to main content
Kamada Ltd. logo

Kamada Ltd. — Investor Relations & Filings

Ticker · KMDA ISIN · IL0010941198 TA Manufacturing
Open in API
Filings indexed 822 across all filing types
Latest filing 2026-04-16 Director's Dealing
Country IL Israel
Listing TA KMDA

About Kamada Ltd.

https://www.kamada.com

Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.

Recent filings

Filing Released Lang Actions
Other Report or Announcement
Director's Dealing Classification · 1% confidence The document is an SEC Form 3 – an Initial Statement of Beneficial Ownership filed under Section 16(a) of the Securities Exchange Act, detailing personal share and option holdings by company directors/officers. This fits the insider reporting category for transactions by directors and executives. Therefore, it is a Director's Dealing filing.
2026-04-16 English
Other Report or Announcement
Report Publication Announcement Classification · 1% confidence The document is a short ‘‘Other Report or Announcement’’ filed under Israeli TASE/ISA rules, stating that a report (Form 3 filings binder) is attached. It does not contain the actual report data but merely notifies investors of its publication/attachment. This fits the definition of a Report Publication Announcement.
2026-04-16 English
Other Report or Announcement
Regulatory Filings
2026-04-10 Hebrew (modern)
Other Report or Announcement
Director's Dealing Classification · 1% confidence The document is filed under Regulation 5 of the Securities Regulations for a foreign private issuer and explicitly states “Attached hereto is a report on Form 4s.” U.S. Form 4 is used for insider share transactions by company directors and executives. This clearly matches the definition for ‘Director’s Dealing’ filings.
2026-04-10 English
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
Regulatory Filings Classification · 1% confidence The document is a Form 6-K “Report of Foreign Private Issuer” filed by Kamada Ltd. to the SEC, containing an update on withholding tax procedures for a previously announced cash dividend. It is not a full financial report (10-K, IR), not an earnings release, nor a standalone management discussion or ESG report, but a regulatory filing under the Exchange Act. It does not fit more specific categories such as dividend notice (DIV) since it merely updates tax procedures rather than announcing the dividend amount itself. Therefore it falls into the fallback category “Regulatory Filings” (RNS).
2026-03-31 English
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
Report Publication Announcement Classification · 1% confidence The document is an “Immediate Report” to the Tel Aviv Stock Exchange/ISA that states the publication date and time (31/03/2026 14:00) and notes that the detailed PDF report on withholding tax procedures is attached (‘Attached hereto is a report…’). It is only announcing the availability of a separate report rather than containing the substantive report itself. Under the “menu vs meal” rule, this is a Report Publication Announcement rather than the report itself.
2026-03-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.